Literature DB >> 3470693

Glucocorticoid receptors predict response to combination chemotherapy in patients with acute lymphoblastic leukemia.

S Iacobelli, P Marchetti, G De Rossi, F Mandelli, N Gentiloni.   

Abstract

Glucocorticoid receptor levels were quantified in leukemic blasts from peripheral blood of 86 patients with acute lymphoblastic leukemia. Subsequent achievement of complete remission correlated with high receptor levels. Forty-seven of 50 patients with leukemic cells containing more than 6,000 receptor sites and 22 of 36 patients with cells containing less than 6,000 receptor sites achieved remission. The study of glucocorticoid receptors in leukemic cells may predict response to combination chemotherapy in acute lymphoblastic leukemia patients.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3470693     DOI： 10.1159/000226435

Source DB:  PubMed          Journal:  Oncology        ISSN： 0030-2414            Impact factor:   2.935


  4 in total

1.  Role for microRNAs in regulating glucocorticoid response and resistance in multiple myeloma.

Authors:  Michael A Tessel; Ashley L Benham; Nancy L Krett; Steven T Rosen; Preethi H Gunaratne
Journal:  Horm Cancer       Date:  2011-06       Impact factor: 3.869

2.  Glucocorticoid resistance in a multiple myeloma cell line is regulated by a transcription elongation block in the glucocorticoid receptor gene (NR3C1).

Authors:  Beatriz Sánchez-Vega; Varsha Gandhi
Journal:  Br J Haematol       Date:  2008-12-26       Impact factor: 6.998

3.  Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1.

Authors:  Christoph J Heuck; Jackie Szymonifka; Emily Hansen; John D Shaughnessy; Saad Z Usmani; Frits van Rhee; Elias Anaissie; Bijay Nair; Sarah Waheed; Yazan Alsayed; Nathan Petty; Clyde Bailey; Joshua Epstein; Antje Hoering; John Crowley; Bart Barlogie
Journal:  Clin Cancer Res       Date:  2012-08-01       Impact factor: 12.531

4.  Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death.

Authors:  Christian Argueta; Trinayan Kashyap; Boris Klebanov; Thaddeus J Unger; Cathy Guo; Susie Harrington; Erkan Baloglu; Margaret Lee; William Senapedis; Sharon Shacham; Yosef Landesman
Journal:  Oncotarget       Date:  2018-05-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.